Cited by 252BRCA gene mutations in cancerPancreatic and Hepatic Oncology ResearchGenetic factors in colorectal cancer

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

Open access

, the Hereditary Breast Cancer Study Group, Iqbal, J, Ragone, A, Lubinski, J, Lynch, H T, Moller, P, Ghadirian, P, Foulkes, W D, Armel, S, Eisen, A, Neuhausen, S L, Senter, L, Singer, C F, Ainsworth, P, Kim-Sing, C, Tung, N, Friedman, E, Llacuachaqui, M, Ping, S, Narod, S A·2012·British Journal of Cancer

DOI 10.1038/bjc.2012.483PMC PMC3516682

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Germline mutations in BRCA1 and BRCA2 predispose to pancreatic cancer. We estimated the incidence of pancreatic cancer in a cohort of female carriers of BRCA1 and BRCA2 mutation. We also estimated survival rates in pancreatic cancer cases from families with a BRCA mutation. METHODS: We followed 5149 women with a mutation for new cases of pancreatic cancer. The standardised incidence ratios (SIR) for pancreatic cancer were calculated based on age group and country of residence. We also reviewed the pedigrees of 8140 pedigrees with a BRCA1 or a BRCA2 mutation for those with a case of pancreatic cancer. We recorded the year of diagnosis and the year of death for 351 identified cases. RESULTS: Eight incident pancreatic cancer cases were identified among all mutation carriers. The SIR for BRCA1 carriers was 2.55 (95% CI=1.03-5.31, P=0.04) and for BRCA2 carriers was 2.13 (95% CI=0.36-7.03, P=0.3). The 5-year survival rate was 5% for cases from a BRCA1 family and 4% for cases from a BRCA2 family. CONCLUSION: The risk of pancreatic cancer is approximately doubled in female BRCA carriers. The poor survival in familial pancreatic cancer underscores the need for novel anti-tumoural strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/bjc.2012.483

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
Cancer risks in BRCA2 mutation carriers.
Olsson, H. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,404
Cancer Incidence in BRCA1 mutation carriers.
Thompson, D., & Easton, D. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.18.1358 · Cited by 1,231
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M. E. M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,132
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826 · cited 2×
“These include BRCA1 and BRCA2 (Lal et al, 2000), TP53 (Caldas et al, 1994), PALB2 (Jones et al, 2009), p16/CDKN2A (Redston et al, 1994; Ghiorzo et al, 2012), SMAD4 (Hahn et al, 1996), STK 11 (Sato et al, 2001), ataxia-telangiectasia-mutated (ATM) gene (Roberts et al, 2011) and the mismatch repair genes (MMR) (Win et a…”
Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B. P., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 678
Self-citation
ATM Mutations in Patients with Hereditary Pancreatic Cancer
Roberts, N. J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., Gallinger, S., Schwartz, A. G., Syngal, S., Cote, M. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0194 · Cited by 491 · cited 1×
“…(Lal et al, 2000), TP53 (Caldas et al, 1994), PALB2 (Jones et al, 2009), p16/CDKN2A (Redston et al, 1994; Ghiorzo et al, 2012), SMAD4 (Hahn et al, 1996), STK 11 (Sato et al, 2001), ataxia-telangiectasia-mutated (ATM) gene (Roberts et al, 2011) and the mismatch repair genes (MMR) (Win et al, 2012).”
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.
Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., da Costa, L., Yeo, C. J., & Kern, S. E. (1994) · PubMed · Cited by 451
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.
Win, A. K., Young, J., Lindor, N., Tucker, K., Ahnen, D., Young, G., Buchanan, D., Clendenning, M., Giles, G., Winship, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5590 · Cited by 324
STK11/LKB1 Peutz-Jeghers Gene Inactivation in Intraductal Papillary-Mucinous Neoplasms of the Pancreas
Sato, N., Rosty, C., Jansen, M., Fukushima, N., Ueki, T., Yeo, C. J., Cameron, J. L., Iacobuzio–Donahue, C. A., Hruban, R. H., & Goggins, M. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63053-2 · Cited by 268

Flagged first, then by citations

Show all 19 references

1 of the 19 references couldn’t be matched to a known paper.

Sorted by citations

Pancreatic adenocarcinoma
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Pancreatic cancer
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Patients Tested at a Laboratory for Hereditary Cancer Syndromes Show an Overlap for Multiple Syndromes in Their Personal and Familial Cancer Histories
Saam, J. R., Arnell, C., Theisen, A. P., Moyes, K., Marino, I., Roundy, K. M., & WENSTRUP, R. J. (2015) · Oncology · doi:10.1159/000437307 · Cited by 1,533
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M. M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V. M., Czito, B. G., Chiaro, M. D., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,356
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O'Byrne, K. J., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 775
Cancers associated with BRCA 1 and BRCA 2 mutations other than breast and ovarian
Mersch, J. A., Jackson, M., Park, M., Nebgen, D. R., Peterson, S. K., Singletary, C. N., Arun, B., & Litton, J. K. (2014) · Cancer · doi:10.1002/cncr.29041 · Cited by 513
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C. H., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 500
Early detection of pancreatic cancer
Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., Li, D., Greenhalf, W., Jeon, C. Y., Koay, E. J., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30416-9 · Cited by 482
Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types
Heeke, A. L., Pishvaian, M. J., Lynce, F. C., Xiu, J., Brody, J. R., Chen, W.-J., Baker, T. M., Marshall, J. L., & Isaacs, C. J. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00286 · Cited by 477
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch–Shimon, S., Kaufman, B., Gershoni‐Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 442
Self-citation
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7401 · Cited by 398
Self-citation
Cell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 344
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Goggins, M. G., Hruban, R. H., Cote, M. L., McWilliams, R. R., Roberts, N. J., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.153 · Cited by 295
DNA Damage Response Genes and the Development of Cancer Metastasis
Broustas, C. G., & Lieberman, H. B. (2014) · Radiation Research · doi:10.1667/rr13515.1 · Cited by 284
Identification of germline genetic mutations in patients with pancreatic cancer
Salo‐Mullen, E. E., O'Reilly, E. M., Kelsen, D. P., Ashraf, A. M., Lowery, M. A., Yu, K. H., Reidy‐Lagunes, D. L., Epstein, A. S., Lincoln, A., Saldia, A., et al. (2015) · Cancer · doi:10.1002/cncr.29664 · Cited by 198
A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals
Harinck, F., Konings, I. C. A. W., Kluijt, I., Poley, J. W., van Hooft, J. E., van Dullemen, H. M., Nio, C. Y., Krak, N. C., Hermans, J. J., Aalfs, C. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308008 · Cited by 185
Inflammation-Induced Cell Proliferation Potentiates DNA Damage-Induced Mutations In Vivo
Kiraly, O., Gong, G., Olipitz, W., Muthupalani, S., & Engelward, B. P. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1004901 · Cited by 169
Familial pancreatic cancer
Petersen, G. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.002 · Cited by 157
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
Lowery, M. A., Kelsen, D. P., Capanu, M., Smith, S., Lee, J. W., Stadler, Z. K., Moore, M. J., Kindler, H. L., Golan, T., Segal, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.004 · Cited by 159
ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations
Sawhney, M., Calderwood, A. H., Thosani, N. C., Rebbeck, T. R., Wani, S. B., Canto, M. I., Fishman, D. S., Golan, T., Hidalgo, M. M., Kwon, R. S., et al. (2022) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2021.12.001 · Cited by 158
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis
Oh, M., McBride, A., Yun, S., Bhattacharjee, S., Slack, M. K., Martin, J. R., Jeter, J., & Abraham, I. L. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy148 · Cited by 140
BRCA mutation in ovarian cancer: testing, implications and treatment considerations
Neff, R. T., Senter, L. A., & Salani, R. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017714993 · Cited by 142
Self-citation
Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors
Ushio, J., Kanno, A., Ikeda, E., Ando, K., Nagai, H., Miwata, T., Kawasaki, Y., Tada, Y., Yokoyama, K., Numao, N., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11030562 · Cited by 132
Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Angeli, D., Salvi, S., & Tedaldi, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031128 · Cited by 132
Inherited DNA-Repair Defects in Colorectal Cancer
AlDubayan, S. H., Giannakis, M., Moore, N. D., Han, G. C., Reardon, B. M., Hamada, T., Mu, X. J., Nishihara, R., Qian, Z., Liu, L., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.01.018 · Cited by 118
BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects
Wong, W., Raufi, A. G., Safyan, R. A., Bates, S. E., & Manji, G. A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s211151 · Cited by 114
State of the art and future directions of pancreatic ductal adenocarcinoma therapy
Neuzillet, C., Tijeras‐Raballand, A., Bourget, P., Cros, J. F., Couvelard, A., Sauvanet, A., Vullierme, M., Tournigand, C., & Hammel, P. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.08.006 · Cited by 114
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2 ) Mutation
Du, C., Qi, Y., Zhang, Y., Wang, Y., Zhao, X., Min, H., Han, X., Lang, J., Qin, H., Shi, Q., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b01573 · Cited by 103
Risk of Pancreatic Cancer in Breast Cancer Families from the Breast Cancer Family Registry
Mocci, E., Milne, R. L., Méndez-Villamil, E. Y., Hopper, J. L., John, E. M., Andrulis, I. L., Chung, W. K., Daly, M. B., Buys, S. S., Malats, N., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0195 · Cited by 97
Environmental risk factors for pancreatic cancer: an update
Barone, E., Corrado, A., Gemignani, F., & Landi, S. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1821-9 · Cited by 100
New therapeutic targets in pancreatic cancer
Lai, E., Puzzoni, M., Ziranu, P., Pretta, A., Impera, V., Mariani, S., Liscia, N., Soro, P., Musio, F., Persano, M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101926 · Cited by 94
Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene
Hsu, F.-C., Roberts, N. J., Childs, E., Porter, N., Rabe, K. G., Borgida, A., Ukaegbu, C., Goggins, M. G., Hruban, R. H., Zogopoulos, G., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3701 · Cited by 91
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Meeks, H., Song, H., Michailidou, K., Bolla, M. K., Dennis, J., Wang, Q., Barrowdale, D., Frost, D., EMBRACE, McGuffog, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv315 · Cited by 90
Self-citation
BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma
Blair, A. B., Groot, V. P., Gemenetzis, G., Wei, J., Cameron, J. L., Weiss, M. J., Goggins, M., Wolfgang, C. L., Yu, J., & He, J. P. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2017.12.021 · Cited by 85
Hereditary breast cancer: syndromes, tumour pathology and molecular testing
Sokolova, A., Johnstone, K. J., Reed, A. E. M., Simpson, P. T., & Lakhani, S. R. (2022) · Histopathology · doi:10.1111/his.14808 · Cited by 95
BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management
Lee, M. V., Katabathina, V. S., Bowerson, M., Mityul, M. I., Shetty, A. S., Elsayes, K. M., Balachandran, A., Bhosale, P., McCullough, A. E., & Menias, C. O. (2017) · Radiographics · doi:10.1148/rg.2017160144 · Cited by 79
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial
Golan, T., Kindler, H. L., Park, J. O., Reni, M., Macarulla, T. M., Hammel, P. R., Cutsem, E. V., Arnold, D., Hochhauser, D., McGuinness, D. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01890 · Cited by 74
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward
Khan, M. A., Azim, S., Zubair, H., Bhardwaj, A., Patel, G. K., Khushman, M. M., Singh, S., & Singh, A. P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040779 · Cited by 73
Genetics and Genetic Testing in Pancreatic Cancer
Whitcomb, D. C., Shelton, C. A., & Brand, R. E. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.057 · Cited by 69
BRCA-mutant pancreatic ductal adenocarcinoma
Lai, E., Ziranu, P., Spanu, D., Dubois, M., Pretta, A., Tolu, S., Camera, S., Liscia, N., Mariani, S., Persano, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01469-9 · Cited by 71
Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants
Silvestri, V., Leslie, G., Barnes, D. R., and the CIMBA Group, Agnarsson, B. A., Aittomäki, K., Alducci, E., Andrulis, I. L., Barkardottir, R. B., Barroso, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2134 · Cited by 66
Self-citation
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease
ter Veer, E., van Rijssen, L. B., Besselink, M. G., Mali, R. M. A., Berlin, J. D., Boeck, S. H., Bonnetain, F., Chau, I., Conroy, T., Cutsem, E. V., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30098-6 · Cited by 66
Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells
Maëda, J., Roybal, E. J., Brents, C. A., Uesaka, M., Aizawa, Y., & Kato, T. A. (2013) · Oncology Reports · doi:10.3892/or.2013.2902 · Cited by 65
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Concannon, K., Morris, B. B., Gay, C. M., & Byers, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.031 · Cited by 71
BRCA1 and Oxidative Stress
Yi, Y. W., Kang, H. J., & Bae, I. (2014) · Cancers · doi:10.3390/cancers6020771 · Cited by 65
Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer
Ohmoto, A., Yachida, S., & Morizane, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030561 · Cited by 58
Familial pancreatic adenocarcinoma
Petersen, G. M. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.007 · Cited by 53
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
O’Shaughnessy, J., Brezden‐Masley, C., Cazzaniga, M. E., Dalvi, T. B., Walker, G., Bennett, J., & Ohsumi, S. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01349-9 · Cited by 54
Emerging strategies in BRCA-positive pancreatic cancer
Kowalewski, A., Szylberg, Ł., Saganek, M., Napiontek, W., Antosik, P., & Grzanka, D. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2666-9 · Cited by 54
Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches
Şahin, İ. H., Lowery, M. A., Stadler, Z. K., Salo‐Mullen, E. E., Iacobuzio–Donahue, C. A., Kelsen, D. P., & O'Reilly, E. M. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1153424 · Cited by 56
Curing pancreatic cancer
Traub, B., Link, K. H., & Kornmann, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.030 · Cited by 51
Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis
Rebelatto, T. F., Falavigna, M., Pozzari, M., Spada, F., Cella, C. A., Laffi, A., Pellicori, S., & Fazio, N. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101895 · Cited by 50
Risk Factors and Therapeutic Targets in Pancreatic Cancer
Wörmann, S. M., & Algül, H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00282 · Cited by 51
Germline mutations in pancreatic cancer and potential new therapeutic options
Pihlak, R., Valle, J. W., & McNamara, M. G. (2017) · Oncotarget · doi:10.18632/oncotarget.17291 · Cited by 48
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers
Streff, H. E., Profato, J., Ye, Y., Nebgen, D. R., Peterson, S. K., Singletary, C. N., Arun, B., & Litton, J. K. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0354 · Cited by 48
Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview
Sikdar, N., Saha, G., Dutta, A., Ghosh, S., Shrikhande, S. V., & Banerjee, S. (2018) · Current Genomics · doi:10.2174/1389202919666180221160753 · Cited by 51
Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management
Yoshimura, A., Imoto, I., & Iwata, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137481 · Cited by 48
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
Hunia, J., Gawalski, K., Szredzka, A., Suskiewicz, M. J., & Nowis, D. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1073797 · Cited by 45
Repeated participation in pancreatic cancer surveillance by high‐risk individuals imposes low psychological burden
Konings, I. C. A. W., Sidharta, G. N., Harinck, F., Aalfs, C. M., Poley, J., Kieffer, J. M., Kuenen, M. A., Smets, E. M. A., Wagner, A., van Hooft, J. E., et al. (2015) · Psycho-Oncology · doi:10.1002/pon.4047 · Cited by 43
Targeting ubiquitin-proteasome pathway by natural, in particular polyphenols, anticancer agents: Lessons learned from clinical trials
Nabavi, S. F., Atanasov, A. G., Khan, H. Z., Barreca, D., Trombetta, D., Testai, L., Sureda, A., Tejada, S., Vacca, R. A., Pittalà, V., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.018 · Cited by 44
Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer
Pavanello, M., Chan, I. H. Y., Ariff, A., Pharoah, P. D. P., Gayther, S. A., & Ramus, S. J. (2020) · Cancers · doi:10.3390/cancers12103046 · Cited by 44
Prevalence and progression of pancreatic cystic precursor lesions differ between groups at high risk of developing pancreatic cancer
Konings, I. C. A. W., Harinck, F., Poley, J.-W., Aalfs, C. M., van Rens, A., Krak, N. C., Wagner, A., Nio, C. Y., Sijmons, R. H., van Dullemen, H. M., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000725 · Cited by 41
Imaging of Pancreatic Neoplasms
Balachandran, A., Bhosale, P., Charnsangavej, C., & Tamm, E. P. (2014) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.07.002 · Cited by 40
Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
Sekine, M., Nishino, K., & Enomoto, T. (2021) · Genes · doi:10.3390/genes12071050 · Cited by 40
Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance
Konings, I. C. A. W., Harinck, F., Kuenen, M. A., Sidharta, G. N., Kieffer, J. M., Aalfs, C. M., Poley, J., Smets, E. M. A., Wagner, A., van Rens, A., et al. (2016) · Familial Cancer · doi:10.1007/s10689-016-9930-4 · Cited by 39
The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go
Thompson, E. D., Roberts, N. J., Wood, L. D., Eshleman, J. R., Goggins, M., Kern, S. E., Klein, A. P., & Hruban, R. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0629-6 · Cited by 41
Therapeutic targeting and patient selection for cancers with homologous recombination defects
Talens, F., Jalving, M., Gietema, J. A., & van Vugt, M. A. T. M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1322061 · Cited by 41
Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers
Laitman, Y., Michaelson‐Cohen, R., Levi, E., Chen‐Shtoyerman, R., Reish, O., Josefsberg, S. B. Y., Bernstein‐Molho, R., Keinan‐Boker, L., Rosengarten, O. S., SILVERMAN, B. G., et al. (2018) · Cancer · doi:10.1002/cncr.31842 · Cited by 38
Self-citation
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines
Dullens, B., Putter, R. D., Lambertini, M., Toss, A., Han, S., Nieuwenhuysen, E. V., Gorp, T. V., Vanderstichele, A., Ongeval, C. V., Keupers, M., et al. (2020) · Journal of Oncology · doi:10.1155/2020/9873954 · Cited by 38
BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in Norway
Heramb, C., Wangensteen, T., Grindedal, E. M., Ariansen, S. L., Lothe, S. M., Heimdal, K., & Mæhle, L. (2018) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-017-0085-6 · Cited by 37
Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation
Vyas, O. H., Leung, K., Ledbetter, L., Kaley, K., Rodríguez, T., Garcon, M. C., & Saif, M. W. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000178 · Cited by 36
Hereditary Pancreatic Cancer Syndromes
Connor, A. A., & Gallinger, S. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.06.007 · Cited by 36
Hereditary pancreatic cancer: related syndromes and clinical perspective
Carrera, S., Sancho, A., Azkona, E., Azkuna, J., & López-Vivanco, G. (2017) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-017-0069-6 · Cited by 36
Epidemiology of HPB malignancy in the elderly
Pericleous, M., & Khan, S. A. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.03.222 · Cited by 38
Potential Usefulness of Apolipoprotein A2 Isoforms for Screening and Risk Stratification of Pancreatic Cancer
Honda, K., & Srivastava, S. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0209 · Cited by 36
Pancreatic cancer: BRCA mutation and personalized treatment
Luo, G., Yu, L., Jin, K., He, C., Guo, M., Liu, Z., Long, J., Liu, C., Ni, Q., & Yu, X. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1086271 · Cited by 34
The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study
Iqbal, J., Nussenzweig, A., Lubiński, J., Byrski, T., Eisen, A. F., Bordeleau, L. J., Tung, N., Manoukian, S., Phelan, C. M., Sun, P., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.58 · Cited by 33
Self-citation
Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment
Verdaguer, H., Saurí, T., & Macarulla, T. M. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.15 · Cited by 32
Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome
Santonocito, C., Rizza, R., Paris, I., Marchis, L. D., Paolillo, C., Tiberi, G., Scambia, G., & Capoluongo, E. (2020) · Cancers · doi:10.3390/cancers12051286 · Cited by 30
American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence
Calderwood, A. H., Sawhney, M., Thosani, N. C., Rebbeck, T. R., Wani, S. B., Canto, M. I., Fishman, D. S., Golan, T., Hidalgo, M. M., Kwon, R. S., et al. (2022) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2021.12.002 · Cited by 30
BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine
Παναγοπούλου, Μ., Panou, T., Γκουντάκος, Α., Tarapatzi, G., Karaglani, M., Tsamardinos, I., & Chatzaki, Ε. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01787-8 · Cited by 34
Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy
Caini, S., Radice, D., Tosti, G., Spadola, G., Cocorocchio, E., Ferrucci, P. F., Testori, A., Pennacchioli, E., Fargnoli, M. C., Palli, D., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13645 · Cited by 29
BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer
Sengodan, S. K., Nadhan, R., Nair, R. S., Hemalatha, S. K., Somasundaram, V., Sushama, R. R., Rajan, A., Latha, N. R., Varghese, G. R., Thankappan, R., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.75 · Cited by 29
High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening
Bruenderman, E. H., & Martin, R. C. G. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.06.046 · Cited by 28
Inherited Cancer in the Age of Next-Generation Sequencing
Price, K. S., Svenson, A., King, E., Ready, K. J., & Lazarin, G. A. (2018) · Biological Research For Nursing · doi:10.1177/1099800417750746 · Cited by 28
PARP-Inhibitors in BRCA-Associated Pancreatic Cancer
Bhalla, A., & Saif, M. W. (2014) · PubMed · doi:10.6092/1590-8577/2690 · Cited by 27
Clinical features and management of BRCA1 and BRCA2-associated prostate cancer.
Alanee, S., Glogowski, E., Schrader, K., Eastham, J., & Offit, K. (2014) · Frontiers in Bioscience · doi:10.2741/e686 · Cited by 24
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis
Page, C. L., Rahimi, K., Rodrigues, M. J., Heinzelmann-Schwarz, V. A., Recio, N., Tommasi, S., Bataillon, G., Portelance, L., Golmard, L., Meunier, L., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.019 · Cited by 27
BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
Marciano, N. D., Kroening, G., Dayyani, F., Zell, J. A., Lee, F.-C., Cho, M. T., & Valerin, J. B. (2022) · Cancers · doi:10.3390/cancers14102453 · Cited by 27
Cancer testis antigens and genomic instability: More than immunology
Jay, A. T., Reitz, D., Namekawa, S. H., & Heyer, W. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103214 · Cited by 30
Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
Perkhofer, L., Golan, T., Cuyle, P.-J. A., Matysiak‐Budnik, T., Laethem, J. V., Macarulla, T. M., Cauchin, E., Kleger, A., Beutel, A. K., Gout, J., et al. (2021) · Cancers · doi:10.3390/cancers13174259 · Cited by 25
A Review of Breast Cancer Risk Factors in Adolescents and Young Adults
McVeigh, U. M., Tepper, J. W., & McVeigh, T. P. (2021) · Cancers · doi:10.3390/cancers13215552 · Cited by 29
BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population
Zhu, Y., Zhai, K., Ke, J., Li, J., Gong, Y., Yang, Y., Tian, J., Zhang, Y., Zou, D., Peng, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16422 · Cited by 24
Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes
Wang, J., Li, W., Shi, Y., Huang, Y., Sun, T., Tang, L., Lü, Q., Lei, Q., Liao, N., Jin, F., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2093 · Cited by 23
Screening for pancreatic cancer has the potential to save lives, but is it practical?
Mazer, B. L., Lee, J. W., Roberts, N. J., Chu, L. C. H., Lennon, A. M., Klein, A. P., Eshleman, J. R., Fishman, E. K., Canto, M. I., Goggins, M., et al. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2217354 · Cited by 24
The development of PARP as a successful target for cancer therapy
Ferrara, R., Simionato, F., Ciccarese, C., Grego, E., Cingarlini, S., Iacovelli, R., Bria, E., Tortora, G., & Melisi, D. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1419870 · Cited by 23
Antioxidant Properties of Zinc and Copper—Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers
Matuszczak, M., Kiljańczyk, A., Marciniak, W., Derkacz, R., Stempa, K., Baszuk, P., Bryśkiewicz, M., Cybulski, C., Dębniak, T., Gronwald, J., et al. (2024) · Antioxidants · doi:10.3390/antiox13070841 · Cited by 24
Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers
de Mestier, L., Danset, J. B., Neuzillet, C., Rebours, V., Cros, J. F., Soufir, N., & Hammel, P. R. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0269 · Cited by 23
Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
Le, D., & Gelmon, K. A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1513321 · Cited by 22
Family storytelling about hereditary cancer: Framing shared understandings of risk
Campbell‐Salome, G., & Rauscher, E. A. (2020) · Journal of Genetic Counseling · doi:10.1002/jgc4.1218 · Cited by 21

Authors: T. H. B. C. S. G., Iqbal, J., Ragone, A., Lubinski, J., Lynch, H. T., Moller, P., Ghadirian, P., Foulkes, W. D., Armel, S., Eisen, A., Neuhausen, S. L., Senter, L., Singer, C. F., Ainsworth, P., Kim-Sing, C., Tung, N., Friedman, E., Llacuachaqui, M., Ping, S., & Narod, S. A.
Affiliations: Women’s College Hospital Research and Innovation Institute (CA)
International Hereditary Cancer Center (PL)
Creighton University (US)
McGill University (CA)
University of Toronto (CA)
Sunnybrook Health Science Centre (CA)
City Of Hope National Medical Center (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Comprehensive Cancer Center Vienna (AT)
BC Cancer Agency (CA)
Beth Israel Deaconess Medical Center (US)
Tel Aviv University (IL)
Corresponding author: Narod, S A
ORCID: Iqbal, J
Foulkes, W D
Armel, S
Eisen, A
Neuhausen, S L
Senter, L
Singer, C F
Ainsworth, P
Tung, N
Friedman, E
Narod, S A
Venue: British Journal of Cancer
Publisher: Springer Science and Business Media LLC
Published: 2012-10-25
Volume: 107
Issue: 12
Pages: 2005-2009
ISSN: 0007-0920 (ISSN-L)
1532-1827
DOI: 10.1038/bjc.2012.483
PMC: PMC3516682
OpenAlex: W2035801850
Cited by: 252
References: 19
Citations by year: 2026: 6 · 2025: 14 · 2024: 6 · 2023: 17 · 2022: 23 · 2021: 20 · 2020: 26 · 2019: 18 · 2018: 19 · 2017: 28 · 2016: 24 · 2015: 20 · 2014: 22 · 2013: 9
FWCI: 9.80
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
www.springer.com/tdm (unspecified)
Locations: British Journal of Cancer (publishedVersion, cc-by-nc-sa)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Funders: Canadian Cancer Society Research Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: pancreatic cancer, BRCA1 mutation carriers, BRCA2 mutation carriers, hereditary cancer predisposition, cancer incidence, standardized incidence ratio, survival rate, familial pancreatic cancer
MeSH terms: Adult, Aged, Female, Heterozygote, Humans, Middle Aged, Pancreatic Neoplasms, Cohort Studies, Incidence, Germ-Line Mutation, BRCA1 Protein, Genes, BRCA1, Genes, BRCA2, BRCA2 Protein, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks